MedTrace Logo

Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative

NCT02773095 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 966

Last updated 2020-04-29

No results posted yet for this study

Summary

Countries throughout the world are facing a growing non-communicable disease (NCD) burden. In developing countries, medicines to treat NCDs are often difficult to access or too expensive for many households. Novartis/Sandoz has recently launched Novartis Access, an initiative to subsidize a basket of NCD medicines sold to purchasers in program countries and delivered through the public and non-profit health sectors. This study will evaluate the impact of Novartis Access on the availability and price of NCD medicines at health facilities and households in Kenya, the first country to receive the program.

Conditions

Interventions

OTHER

Novartis Access

Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.

Sponsors & Collaborators

  • Innovations for Poverty Action

    collaborator OTHER

  • Boston University

    lead OTHER

Principal Investigators

  • Richard Laing, MD · Boston University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-11-30
Completion
2019-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02773095 on ClinicalTrials.gov